多奈哌齐治疗血管性痴呆疗效观察  

Study on the efect of donepezil for treating vascular dementia

作　　者：柳祥忠[1] 

机构地区：[1]安阳钢铁集团公司职工总医院神经内科,河南省安阳455004

出　　处：《中国基层医药》2008年第1期58-59,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察多奈哌齐治疗血管性痴呆患者轻、中度认知功能障碍的疗效和安全性。方法46例血管性痴呆患者以SAS软件分为治疗组和对照组各23例。治疗组服用多奈哌齐片5mg，每晚睡前服；对照组服用脑蛋白水解物3次／d，2粒／次口服，疗程均为90d。以简易精神状态检查（MMSE）和中国修订成人韦克斯勒智力量表（WAIS-RC）为主要评价指标，日常生活活动能力量表（ADL）和临床综合调查表（CGI）为次要评价指标评价临床疗效。结果两组MMSE评分在治疗后均明显提高（P〈0.01）；WAIS-RC评分治疗组治疗后明显提高（P〈0．01），对照组治疗前后WAIS-RC评分差异无统计学意义（P〉0．05）；两组治疗后ADL和CGI的SI均降低，两组药物相关的不良反应差异无统计学意义。结论多奈哌齐能改善血管性痴呆患者的认知功能，疗效可能优于脑蛋白水解物，应用多奈哌齐5mg／d比较安全。Objective To assess the clinical efficacy and safety of donepezil in treating the mild to moderate cognitive impairment of vascular dementia. Methods 46 patients with vascular dementia were randomly divided into therapy group（donepezil 5mg/d） and control group（naofukang,3/d）. All patients were assessed with mini-mantal state examination（MMSE）, wechsler aduh intelligence-revised in China（WAIRC）, activities of daily living（ADL）, and clinical global impression（CGI）, before and 90 days after treatment. Results MMSE scores improved significantly in both groupsafter the treatment. The therapy group produced significantly better scores than the control groups on the MMSE（ P 〈 0.05）. WAIRC scores improved significantly in the therapy groups（ P 〈 0.01 ）, but there was no significant difference for control groups（ P 〉 0.05 ）, before and after treatment. Severity improvement （SI） score of ADL and CGI in the both groups decreased. There was no significant difference in adverse effects between two groups. Conclusion Donepezil can improve the cognitive function of patients with vascular dementia, which seems better than that of naofukang,and it is fairly safe for vascular dementia patients to take donepezil 5mg a day.

关 键 词：血管性痴呆 多奈哌齐 治疗 疗效 安全性 

分 类 号：R749.13[医药卫生—神经病学与精神病学] R749.16[医药卫生—临床医学]